Pregled bibliografske jedinice broj: 1015501
The Reverse Payment Settlements in the European Pharmaceutical Market
The Reverse Payment Settlements in the European Pharmaceutical Market // Europeanization and Globalization, vol. 5, Personalized Medicine in Healthcare Systems, Legal, Medical and Economic Implications / Bodiroga – Vukobrat, Nada ; Rukavina, Daniel ; Pavelić, Krešimir ; Sander, Gerald G (ur.).
Heidelberg: Springer, 2019. str. 241-253 doi:10.1007/978-3-030-16465-2
CROSBI ID: 1015501 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The Reverse Payment Settlements in the European Pharmaceutical Market
Autori
Pošćić, Ana
Vrsta, podvrsta i kategorija rada
Poglavlja u knjigama, znanstveni
Knjiga
Europeanization and Globalization, vol. 5, Personalized Medicine in Healthcare Systems, Legal, Medical and Economic Implications
Urednik/ci
Bodiroga – Vukobrat, Nada ; Rukavina, Daniel ; Pavelić, Krešimir ; Sander, Gerald G
Izdavač
Springer
Grad
Heidelberg
Godina
2019
Raspon stranica
241-253
ISBN
978-3-030-16464-5
ISSN
2366-0953
Ključne riječi
Competition Law, Reverse Payment Settlements, Pharmaceutical Market, European Law
Sažetak
This chapter analyses the novelties in the EU competition law in pharmaceutical sector. Decisions in cases Lundbeck, Servier and J&J/Novartis reveal the Commission’s approach to intellectual property and regulatory issues which delay the market entry of generic pharmaceuticals. This contribution exposes and analyses a recent practice applied by pharmaceutical undertakings as part of their strategy to keep the dominant position in the market. It involves settlements between producers of original and generic pharmaceuticals, under which the producers of original pharmaceuticals undertake the obligation to pay generic producers in exchange for delay of market entry of generic pharmaceuticals. Such settlements are called reverse patent settlements or so-called ‘pay for delay’ settlements.
Izvorni jezik
Engleski
Znanstvena područja
Pravo
